Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials

C. Daniel Mullins, Danielle Whicher, Emily S. Reese, Sean Tunis

Research output: Contribution to journalArticle

Abstract

Comparative effectiveness research (CER), or research design to meet the needs of post-regulatory decision makers, has been brought into the spotlight with the introduction of the American Recovery and Reinvestment Act, which provided $US1.1 billion over 2 years to support CER. In the short run, the majority of this money will be invested in observational studies and building of infrastructure; however, in the long run, we will likely see an increase in the number of randomized controlled trials (RCTs), as this method is arguably the most unbiased approach for establishing causal effect between treatments and health outcomes. RCTs are an integral component of CER for generating credible evidence on the relative value of alternative interventions in order to meet the needs of post-regulatory decision makers (patients, physicians, payers and policy makers).Explanatory phase III RCTs are fit for purpose; researchers make use of guidance documents produced by the US FDA to inform the design of these clinical trials. Historically, without explicit FDA guidance, broad patient populations, including women and minorities, often were not considered in trial design. In addition, attempts to minimize cost and maximize efficiency have led to smaller sample sizes, as is clear from the increase in 'creeping phase II-ism'. To demonstrate effectiveness, RCTs must be reflective of how an intervention will be used in the healthcare market. The concept of pragmatic clinical trials has emerged to describe those trials that are designed explicitly with this need in mind. Use of pragmatic trials will be most impactful if post-regulatory decision makers are engaged in the development of recommendations for trial design features, such as indicating outcomes measures and articulating patient populations of interest, which clearly express their evidence needs.

Original languageEnglish (US)
Pages (from-to)969-976
Number of pages8
JournalPharmacoEconomics
Volume28
Issue number10
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Comparative Effectiveness Research
Randomized Controlled Trials
Pragmatic Clinical Trials
American Recovery and Reinvestment Act
Health Care Sector
Administrative Personnel
Sample Size
Population
Observational Studies
Research Design
Research Personnel
Outcome Assessment (Health Care)
Clinical Trials
Physicians
Costs and Cost Analysis
Health

Keywords

  • clinical-trial-design
  • randomised-controlled-trials
  • treatment-outcome

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. / Mullins, C. Daniel; Whicher, Danielle; Reese, Emily S.; Tunis, Sean.

In: PharmacoEconomics, Vol. 28, No. 10, 2010, p. 969-976.

Research output: Contribution to journalArticle

Mullins, C. Daniel ; Whicher, Danielle ; Reese, Emily S. ; Tunis, Sean. / Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. In: PharmacoEconomics. 2010 ; Vol. 28, No. 10. pp. 969-976.
@article{c46299a026094c45b7c2a779e7e03626,
title = "Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials",
abstract = "Comparative effectiveness research (CER), or research design to meet the needs of post-regulatory decision makers, has been brought into the spotlight with the introduction of the American Recovery and Reinvestment Act, which provided $US1.1 billion over 2 years to support CER. In the short run, the majority of this money will be invested in observational studies and building of infrastructure; however, in the long run, we will likely see an increase in the number of randomized controlled trials (RCTs), as this method is arguably the most unbiased approach for establishing causal effect between treatments and health outcomes. RCTs are an integral component of CER for generating credible evidence on the relative value of alternative interventions in order to meet the needs of post-regulatory decision makers (patients, physicians, payers and policy makers).Explanatory phase III RCTs are fit for purpose; researchers make use of guidance documents produced by the US FDA to inform the design of these clinical trials. Historically, without explicit FDA guidance, broad patient populations, including women and minorities, often were not considered in trial design. In addition, attempts to minimize cost and maximize efficiency have led to smaller sample sizes, as is clear from the increase in 'creeping phase II-ism'. To demonstrate effectiveness, RCTs must be reflective of how an intervention will be used in the healthcare market. The concept of pragmatic clinical trials has emerged to describe those trials that are designed explicitly with this need in mind. Use of pragmatic trials will be most impactful if post-regulatory decision makers are engaged in the development of recommendations for trial design features, such as indicating outcomes measures and articulating patient populations of interest, which clearly express their evidence needs.",
keywords = "clinical-trial-design, randomised-controlled-trials, treatment-outcome",
author = "Mullins, {C. Daniel} and Danielle Whicher and Reese, {Emily S.} and Sean Tunis",
year = "2010",
doi = "10.2165/11536160-000000000-00000",
language = "English (US)",
volume = "28",
pages = "969--976",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials

AU - Mullins, C. Daniel

AU - Whicher, Danielle

AU - Reese, Emily S.

AU - Tunis, Sean

PY - 2010

Y1 - 2010

N2 - Comparative effectiveness research (CER), or research design to meet the needs of post-regulatory decision makers, has been brought into the spotlight with the introduction of the American Recovery and Reinvestment Act, which provided $US1.1 billion over 2 years to support CER. In the short run, the majority of this money will be invested in observational studies and building of infrastructure; however, in the long run, we will likely see an increase in the number of randomized controlled trials (RCTs), as this method is arguably the most unbiased approach for establishing causal effect between treatments and health outcomes. RCTs are an integral component of CER for generating credible evidence on the relative value of alternative interventions in order to meet the needs of post-regulatory decision makers (patients, physicians, payers and policy makers).Explanatory phase III RCTs are fit for purpose; researchers make use of guidance documents produced by the US FDA to inform the design of these clinical trials. Historically, without explicit FDA guidance, broad patient populations, including women and minorities, often were not considered in trial design. In addition, attempts to minimize cost and maximize efficiency have led to smaller sample sizes, as is clear from the increase in 'creeping phase II-ism'. To demonstrate effectiveness, RCTs must be reflective of how an intervention will be used in the healthcare market. The concept of pragmatic clinical trials has emerged to describe those trials that are designed explicitly with this need in mind. Use of pragmatic trials will be most impactful if post-regulatory decision makers are engaged in the development of recommendations for trial design features, such as indicating outcomes measures and articulating patient populations of interest, which clearly express their evidence needs.

AB - Comparative effectiveness research (CER), or research design to meet the needs of post-regulatory decision makers, has been brought into the spotlight with the introduction of the American Recovery and Reinvestment Act, which provided $US1.1 billion over 2 years to support CER. In the short run, the majority of this money will be invested in observational studies and building of infrastructure; however, in the long run, we will likely see an increase in the number of randomized controlled trials (RCTs), as this method is arguably the most unbiased approach for establishing causal effect between treatments and health outcomes. RCTs are an integral component of CER for generating credible evidence on the relative value of alternative interventions in order to meet the needs of post-regulatory decision makers (patients, physicians, payers and policy makers).Explanatory phase III RCTs are fit for purpose; researchers make use of guidance documents produced by the US FDA to inform the design of these clinical trials. Historically, without explicit FDA guidance, broad patient populations, including women and minorities, often were not considered in trial design. In addition, attempts to minimize cost and maximize efficiency have led to smaller sample sizes, as is clear from the increase in 'creeping phase II-ism'. To demonstrate effectiveness, RCTs must be reflective of how an intervention will be used in the healthcare market. The concept of pragmatic clinical trials has emerged to describe those trials that are designed explicitly with this need in mind. Use of pragmatic trials will be most impactful if post-regulatory decision makers are engaged in the development of recommendations for trial design features, such as indicating outcomes measures and articulating patient populations of interest, which clearly express their evidence needs.

KW - clinical-trial-design

KW - randomised-controlled-trials

KW - treatment-outcome

UR - http://www.scopus.com/inward/record.url?scp=77956555569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956555569&partnerID=8YFLogxK

U2 - 10.2165/11536160-000000000-00000

DO - 10.2165/11536160-000000000-00000

M3 - Article

C2 - 20831305

AN - SCOPUS:77956555569

VL - 28

SP - 969

EP - 976

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 10

ER -